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bjectives We sought to characterize the utilization and impact of a conservative medical manage-
ent strategy for patients with non–ST-segment elevation acute coronary syndromes (NSTE ACS)
nd signiﬁcant coronary artery disease on early angiography.
ackground Practice guidelines recommend an early invasive management strategy for NSTE ACS,
ut revascularization procedures may not always be performed after early angiography, even when
igniﬁcant coronary artery disease is present.
ethods We evaluated 8,225 intermediate- to high-risk NSTE ACS patients with at least 1 coronary le-
ion 50% stenosis on early angiography from the SYNERGY (Superior Yield of the New Strategy of
noxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors) trial (2001 to 2003), comparing patients
reated with conservative medical management with those who underwent in-hospital percutaneous
oronary intervention (PCI) or coronary artery bypass grafting (CABG) within 7 days of randomization.
esults A total of 2,633 patients (32%) were medically managed, 4,294 (52%) underwent PCI, and
,298 (16%) underwent CABG. The strongest independent predictors of conservative medical man-
gement versus any intervention were prior CABG, lower body weight, lack of a reinfarction be-
ween randomization and catheterization, and 3-vessel disease. With conservative medical manage-
ent, the cumulative risk of 1-year mortality after discharge increased rapidly during the ﬁrst 90
ays and thereafter remained higher at 7.7% compared with that seen in patients treated with PCI
3.6%) or CABG (6.2%).
onclusions One-third of patients with NSTE ACS and signiﬁcant coronary disease on early angiog-
aphy were managed without in-hospital revascularization in the SYNERGY trial, and these patients
ad an increased risk of late mortality. These ﬁndings highlight the need for novel treatment ap-
roaches for NSTE ACS patients who are not candidates for revascularization. (SYNERGY trial;
CT00043784) (J Am Coll Cardiol Intv 2008;1:369–78) © 2008 by the American College of
ardiology Foundation
rom the *Duke Clinical Research Institute, Durham, North Carolina; †Green Lane Cardiovascular Service, Auckland City
ospital, Auckland, New Zealand; ‡Flinders Medical Center, Adelaide, Australia; and the §Texas Heart Institute, St.
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370linical practice guidelines recommend an early invasive
anagement treatment strategy for intermediate- to high-
isk patients with non–ST-segment elevation acute coronary
yndromes (NSTE ACS) (1,2). However, angiography is a
iagnostic procedure that does not confer treatment benefit
f patients do not undergo a subsequent revascularization
rocedure (3). In 4 randomized trials comparing conserva-
ive medical management with early invasive management
or NSTE ACS, the majority of patients had significant
oronary disease identified on angiography in the early
nvasive treatment arms (75% to 87%), but the use of
n-hospital percutaneous coronary intervention (PCI) or
oronary artery bypass grafting (CABG) varied from 59% to
2% (4–7). Data from a contemporary registry showed that
pproximately 25% of NSTE ACS patients with 3-vessel
isease did not undergo revascularization (8). These data
uggest that many NSTE ACS patients in contemporary
ractice with significant coronary artery disease (CAD) on
arly angiography do not undergo early revascularization,
but the long-term consequences
of a conservative medical man-
agement approach have not been
fully explored.
We, therefore, sought to de-
scribe the prevalence and predic-
tors of a conservative medical
management treatment strategy
for patients with NSTE ACS and
significant CAD on early angiog-
raphy, and to investigate the long-
term risk of adverse outcomes in
these patients compared with that
seen in patients who underwent
revascularization.
ethods
tudy design and subjects. We performed a subgroup anal-
sis of patients with significant disease on coronary angiog-
aphy enrolled in the SYNERGY (Superior Yield of the
ew Strategy of Enoxaparin, Revascularization, and Gly-
oprotein IIb/IIIa Inhibitors) trial, which randomized 9,978
atients from 12 countries between August 2001 and
ecember 2003 (9,10). The SYNERGY trial was an
pen-label trial designed to evaluate the efficacy and safety
f enoxaparin versus unfractionated heparin when adminis-
ered with established guidelines-recommended therapy in
atients with NSTE ACS planned for an early invasive
trategy. Patients were eligible for study participation if they
ad 2 of the following high-risk features: age 60 years,
T-segment changes, and a troponin or creatine kinase-MB
evel exceeding the upper limit of normal. The majority of
ubjects underwent cardiac catheterization during the initial
bbreviations
nd Acronyms
ABG  coronary artery
ypass grafting
AD  coronary artery
isease
ES  drug-eluting stent(s)
RACE  Global Registry of
cute Coronary Events score
I  myocardial infarction
STE ACS  non–ST-
egment elevation acute
oronary syndromes
CI  percutaneous
oronary interventionospitalization (92%).We included only patients who underwent cardiac cath-
terization during the initial hospitalization with 1 or more
esions 50% severity in a native epicardial coronary artery
left main, left anterior descending, circumflex artery, or
ight coronary artery) or a major side branch of a native
rtery. Angiographic lesion severity was recorded by site
nvestigators without utilization of an angiographic core
aboratory. We excluded patients who did not undergo
atheterization during the initial hospitalization (n  880)
nd patients with normal coronaries on angiography or all
esions on angiography 50% (n  873), as these patients
ould not be candidates for revascularization (Fig. 1).
utcomes ascertainment. Data on in-hospital outcomes
ere obtained by reviewing clinical records for all enrolled
atients. Outcomes after discharge were captured by con-
acting patients by telephone or through scheduled patient
isits through 1 year, and 1-year mortality was ascertained
hrough medical records or national death indexes. Adjudi-
ation was performed for all nonfatal myocardial events
ccurring through 6 months. The total number of subjects
ho were lost to follow-up for the mortality end point at 6
nd 12 months were 16 and 35, respectively.
tatistical methods. UNADJUSTED ANALYSIS. We divided the
tudy population into 3 groups: 1) those who underwent
n-hospital PCI; 2) those who underwent in-hospital
ABG; and 3) those who were medically managed without
n-hospital revascularization performed within 7 days of
andomization. Data were displayed as percentages for
ategorical variables and medians (25th percentile, 75th
ercentile) for continuous variables. Comparison of baseline
haracteristics, angiographic results, in-hospital medication
se, and outcomes was performed using the Pearson chi-
quare test for categorical variables and the Kruskal-Wallis
est for continuous variables. The Global Registry of Acute
oronary Events (GRACE) score has been established as a
obust tool for predicting 6-month post-discharge mortality
n patients with ACS (11). In order to provide a single
2633 MM 4294 PCI 1298 CABG
83 Underwent 
catheterization after 7 
days
9188 Underwent 
in-hospital 
catheterization
8225 Significant CAD
880 Normal 
coronaries/minor 
CAD
9105 Underwent 
in-hospital 
catheterization within 7 
days
Figure 1. Subject Flow
CABG  coronary artery bypass grafting; CAD  coronary artery disease;
MM  conservative medical management; PCI  percutaneous coronary
intervention.
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371umerical estimate of risk for each of the 3 treatment
roups, we calculated the GRACE risk scores for all
ubjects studied. Unadjusted in-hospital events rates in the
groups were compared using the chi-square test, while
ong-term event rates were estimated using the Kaplan-
eier method with pairwise comparisons between groups
ade using the log-rank test.
REDICTORS OF IN-HOSPITAL REVASCULARIZATION. We
eveloped a logistic regression model to identify significant
redictors of in-hospital conservative medical management
ersus in-hospital revascularization (Model 1) using both
tepwise and backward selection techniques on 37 candidate
redictors derived from a large observational registry of
STE ACS patients (12). Nonfatal clinical outcomes
aptured before catheterization were entered as predictors in
he model. The spline transformation method was used to
etermine the functional form for continuous variables that
id not meet linearity assumptions. Whenever appropriate,
e applied piecewise linear splines as the preferred method
f transformation. A p value of 0.05 was used as the
riterion for variable entry and retention in the model.
OST-DISCHARGE MORTALITY. To evaluate the association
etween conservative medical management and long-term
utcomes, we developed a proportional hazards model
omparing the conservative medical management group
ith the PCI and CABG groups individually (conservative
edical management vs. PCI and conservative medical
anagement vs. CABG), as patients undergoing PCI and
ABG often have very different clinical profiles (13). We
xamined the association between conservative medical
anagement as an independent variable and death (all-
ause mortality) or myocardial infarction (MI) at 6 months
s a dependent variable occurring after a discharge landmark
ime point, defined as time of discharge, or 7 days from
andomization if hospitalization was prolonged (Model 2).
odeling outcomes using a landmark time point enabled
ccounting for the ascertainment bias expected when com-
aring early MI rates between conservative medical man-
gement patients (in whom markers were drawn only when
suspected recurrent ischemic event occurred) and PCI or
ABG patients (in whom serial markers were recom-
ended to be routinely drawn post-procedure); as such a
omparison artificially inflates the relative rate of MI in the
CI and CABG groups (14). The use of a discharge
andmark further permitted the modeling of nonfatal events
ccurring before the landmark time point, including recur-
ent ischemia, recurrent MI, acute heart failure, stroke, and
ajor bleeding, as time-updated covariates reflecting
hanges in dynamic risk status (15). We then adjusted
odel 2 for the propensity for in-hospital conservative
edical management by including propensity scores derived
rom data captured before catheterization (Model 1) as a
ovariate in Model 2. fIME-DEPENDENT COVARIATE ANALYSIS. We developed a
ox proportional hazards model that included conservative
edical management versus PCI and conservative medical
anagement versus CABG as time-dependent covariates
nd death from catheterization through 1 year as the
utcome variable (Model 3). Time-dependent covariates
ccount for the timing of PCI and CABG relative to the
ime of catheterization and the outcome of interest, there-
ore serving as a means to reduce survivor bias (16).
All p values were two-tailed and alpha set at 0.05 with
onfidence intervals calculated to the 95th percentile. Sta-
istical analyses were performed using SAS version 8.2 (SAS
nstitute Inc., Cary, North Carolina).
esults
tilization of revascularization procedures. A total of 8,225
atients were found to have significant CAD on early
ngiography, and 4,752 of these patients (57.8%) were
nrolled from U.S. sites. In-hospital revascularization before
he discharge landmark time point was performed in 5,592
atients (68%), with 4,294 patients undergoing PCI
52.2%) and 1,298 patients undergoing CABG (15.8%).
he median time from randomization to cardiac catheter-
zation was 21 (6, 42) h, while the median times from
atheterization to PCI and CABG were 0.5 (0.2, 1.2) h and
4.8 (23.5, 136.1) h, respectively. A total of 2,633 patients
32%) were medically managed without in-hospital revas-
ularization before the discharge landmark time point
Fig. 1).
linical characteristics. Compared with patients undergoing
n-hospital revascularization (PCI/CABG), patients in the
onservative medical management group were older, more
ikely to be women, and more likely to have peripheral
ascular disease, prior stroke, hypertension, diabetes melli-
us, hypercholesterolemia, prior CABG, and lower creati-
ine clearance values (Table 1). The median GRACE risk
core was similar for the CABG group at 124 (110, 141)
nd conservative medical management group at 121 (106,
36), but was lower for the PCI group at 103 (90, 119).
ngiographic results. Patients in the CABG group had the
reatest frequency of left main and 3-vessel disease, while
atients in the PCI group had the greatest frequency of 1-
r 2-vessel disease (Table 2). More than half of the patients
n the conservative medical management group had 3-vessel
isease. Median left ventricular ejection fraction values were
owest in the conservative medical management and CABG
roups.
oncomitant medication utilization. The use of aspirin,
eta-blockers, angiotensin-converting enzyme inhibitors,
nd statins was high in all groups during the initial hospi-
alization, at discharge, and at 30 days (Table 3). The use of
vidence-based medications was highest in the PCI group
ollowed by the conservative medical management group.
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372redictors of conservative medical management. Several
ariables were independently associated with conservative
edical management (Table 4). The strongest predictors of
onservative medical management were prior CABG, lower
ody weight, lack of a recurrent MI from randomization
ntil the time of catheterization, and 3-vessel disease
emonstrated on angiography.
Table 1. Baseline Characteristics
Characteristic
MM
(n  2,633)
Median age, yrs 15.3 (9.5, 21.0)
Female gender, % 32.8
Race, %
White 83.6
Black 7.3
Asian 1.9
Hispanic 4.6
U.S. enrollment, % 44.4
Hypertension, % 70.9
Diabetes, % 33.3
Smoking, % 35.6
Hypercholesterolemia, % 61.8
Prior MI, % 34.2
Prior heart failure, % 12.2
History of stroke, % 6.1
History of PVD, % 11.9
Prior CABG, % 23.0
Prior PCI, % 22.5
Hours from symptom onset (quartiles 1 and 3) 15.3 (9.5, 21.0)
Killip class II–IV, % 14.8
Systolic BP, mm Hg 132 (118, 150)
Heart rate, beats/min 70 (62, 81)
Creatinine clearance, ml/min* 71.1 (53.6, 92.5)
ST-segment depression on ECG, % 57.5
Elevated cardiac enzymes, %† 64.4
Values in parentheses are 25th, 75th percentile. *Creatinine clearance calculated using the Cockrof
BP blood pressure; CABG coronary artery bypass grafting; ECG electrocardiogram;MIm
PVD peripheral vascular disease.
Table 2. Angiography and LV Function
MM
(n  2,633)
PCI
(n  4,294)
CABG
(n  1,298) p Value
Angiographic data,
number (%)*
0.001
Left main disease 9.8 3.9 28.1
1-vessel disease† 24.2 37.2 3.4
2-vessel disease† 22.9 33.7 17.1
3-vessel disease† 52.9 29.1 79.5
LVEF, %‡ 50 (40, 60) 55 (45, 61) 50 (40, 60) 0.001
Values in parentheses are 25th, 75th percentile. *Number of patients with50% stenosis in each
of the following epicardial arteries: left main, left anterior descending, circumflex, or right
coronary artery; †Excluding left main disease; ‡Left ventricular ejection fraction (LVEF)
determined by echocardiography, cardiac catheterization, or radionuclide angiography.tLV left ventricular; other abbreviations as in Table 1.evascularization procedures during follow-up. Overall,
ates of late or repeat revascularization occurring after
ischarge were low (Fig. 2A). Patients who underwent
n-hospital CABG before 7 days were the least likely to
ndergo repeat revascularization procedures, while the rate
f late revascularization was similar in the conservative
edical management and PCI groups. The median time to
ate revascularization (PCI) after discharge for the conser-
ative medical management group was substantially shorter
han the median time to repeat revascularization for those
atients who had received PCI/CABG during the index
ospitalization (Fig. 2B).
n-hospital outcomes. Unadjusted in-hospital events occur-
ing between catheterization and the discharge landmark
ime point occurred most frequently in the CABG group
Table 5). However, the in-hospital mortality curves ap-
eared to be similar for the 3 comparison groups (Fig. 3A).
ost-discharge outcomes. Unadjusted post-discharge events
ccurred most frequently in the conservative medical man-
gement group (Table 6). The post-discharge mortality
urves demonstrated an early hazard for both the conserva-
PCI
(n  4,294)
CABG
(n  1,298) p Value
67 (60, 74) 67 (61, 74) 0.001
31.7 25.9 0.001
0.001
87.4 85.5
5.4 6.3
0.7 0.8
4.7 5.5
59.5 79.1 0.001
65.8 70.3 0.001
26.2 33.2 0.001
34.2 36.1 0.001
59.4 60.0 0.144
25.9 23.4 0.001
6.5 6.8 0.001
3.8 5.2 0.001
8.7 9.1 0.001
16.1 6.7 0.001
21.6 15.2 0.001
14.4 (8.1, 20.5) 14.3 (8.0, 20.4) 0.001
8.9 13.1 0.001
130 (117, 146.0) 130 (117, 147) 0.033
70 (62, 80) 72 (64, 83) 0.001
79.2 (60.6, 101.8) 77.4 (57.8, .98.6) 0.001
53.0 59.6 0.001
70.2 69.9 0.001
formula; †troponin or creatine kinase-MB fraction above the upper limit of normal.
l infarction; MM conservativemedical management; PCI percutaneous coronary intervention;t-Gault
yocardiaive medical management and CABG groups, but after 90
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373ays, the curves diverged and the mortality hazard appeared
igher in the conservative medical management group (Fig.
B). Because the conservative medical management group
ad both an increased rate of post-discharge revasculariza-
ion procedures and an earlier median time to revascular-
zation compared with the PCI and CABG groups, we
epeated the landmark analysis excluding all medically
anaged patients with revascularization performed after the
andmark time point (discharge or 7 days) through 30 days
Table 3. Evidence-Based Medication Use at Baseline, Discharge,
and 30 Days
MM
(n  2,633)
PCI
(n  4,294)
CABG
(n 1,298) p Value
In-hospital
Aspirin, % 94.8 96.0 94.8 0.032
Beta-blocker, % 85.7 87.2 91.2 0.001
ACE inhibitor, % 67.6 61.3 62.6 0.001
Statin, % 71.6 71.9 71.2 0.869
Clopidogrel, % 52.8 84.3 34.8 0.001
At discharge
Aspirin, % 90.7 96.1 89.7 0.001
Beta-blocker, % 85.4 90.1 80.2 0.001
ACE inhibitor, % 75.2 77.5 55.8 0.001
Statin, % 82.4 86.7 70.9 0.001
Clopidogrel, % 37.9 84.2 14.2 0.001
At 30 days
Aspirin, % 90.3 93.5 88.7 0.001
Beta-blocker, % 85.4 87.0 78.7 0.001
ACE inhibitor, % 72.2 72..9 57.5 0.001
Statin, % 82.1 85.5 74.1 0.001
Clopidogrel, % 35.5 68.8 13.9 0.001
ACE angiotensin-converting enzyme; other abbreviations as in Table 1.
Table 4. Independent Predictors of Conservative Medical Management (Mo
Predictor Wa
History of prior CABG
Body weight per 10 kg decrease
MI from randomization to time of catheterization
3-vessel disease
Non-U.S. site
History of prior heart failure
Time from symptom onset to presentation (per hour increase)
Black race
Killip class II–IV
History of prior MI
Diabetes mellitus
Age (per 10-yr increase)
The following variables were entered into the multiple logistic regression model: age (per 10-year
10-kgdecrease; diabetes; hypertension; hyperlipidemia; family history of coronary artery disease; his
percutaneous coronary intervention and prior peripheral vascular disease; pre-randomization use o
Hgdecrease; ST-T changesonelectrocardiography; positive cardiacbiomarkers; triple-vessel disease
([re]-MI, stroke, new-onset heart failure, cardiogenic shock, TIMI [Thrombolysis In Myocardial Infarcbleeding). Model chi-square 367.6, degrees of freedom 17, c-index 0.64, Hosmer and Lemeshow goTable 6, bottom). We observed that the unadjusted and
djusted risk of MI declined in the conservative medical
anagement group when events through 30 days were
ensored, but the adjusted risks of 6-month and 1-year
ortality remained similar.
verall outcomes. We analyzed overall mortality at 1 year
ver a period of observation that included both the in-
ospital and post-discharge time periods (Fig. 4). The early
isk of death from CABG was seen in the first 90 days, but,
fter that period, the risk in the medical cohort increased at
greater rate and the 2 curves cross. Thus, for those who
urvived the initial surgery, the risk became less than that of
he medically treated patients with time. Overall mortality
as highest in the medically managed group and lowest in
he PCI group, with the difference persisting even after
djusting for conservative medical management as a time-
ependent covariate (Table 7).
iscussion
ur study showed that, in a fairly contemporary cohort of
igh-risk NSTE ACS managed with an early invasive
anagement strategy, the majority of which were from U.S.
ites, a substantial proportion of patients did not receive
n-hospital revascularization despite documentation of sig-
ificant coronary disease on angiography. Medically man-
ged patients had a higher risk of long-term adverse
utcomes despite widespread utilization of evidence-based
edications beyond the initial hospitalization.
se of revascularization after early catheterization. Most
bservational studies and randomized controlled trials
tudying early invasive management strategies for NSTE
)
-Square Odds Ratio 95% Confidence Interval
7 1.44 1.25–1.64
1 1.10 1.05–1.14
5 0.21 0.11–0.42
0 1.33 1.17–1.50
7 1.69 1.33–2.14
7 1.48 1.24–1.77
8 1.01 1.00–1.01
0 1.42 1.17–1.74
7 1.33 1.13–1.56
0 1.22 1.08–1.36
6 1.15 1.03–1.29
3 1.07 1.01–1.13
); gender; race; nationality; smoking status; creatinine clearance (per 10 ml/min); body weight per
riormyocardial infarction (MI); prior heart failure; prior coronary artery bypass grafting (CABG); prior
, clopidogrel, warfarin, and/or beta-blockers; Killip class II to IV; systolic blood pressure per 10 mm
naryangiogram; and in-hospital eventsoccurring fromrandomization to the timeof catheterization
ow grade major, or GUSTO [Global Use of Strategies To Open Occluded Coronary Arteries] severedel 1
ld Chi
27.
25.
20.
20.
18.
18.
15.
12.
11.
11.
6.
6.
increase
tory of p
f aspirin
oncoro
tion] flodness-of-fit test, p 0.8.
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374CS have focused on early catheterization rather than early
evascularization as a management strategy (4–7). The
otential consequences of this approach were highlighted by
 recent meta-analysis of clinical trials of early invasive
anagement in NSTE ACS in which the survival benefit
ith an early invasive strategy was most evident when there
as proportionally greater use of revascularization in the
nvasive versus conservative treatment arms (17). While a
ecent analysis from the SYNERGY trial examined out-
omes in NSTE ACS patients undergoing CABG for
ntermediate- to high-risk NSTE ACS, this analysis did not
ocus upon patients with angiographically defined signifi-
ant coronary disease, so the medical management popula-
ion was diluted with patients with insignificant coronary
isease (18). Our study demonstrates that many patients
ith NSTE ACS and significant coronary disease are
Late or repeat 
revascularization rates 
after discharge*
9.0%
3.8%
7.4%
2.3%
0.2%
1.6%
0%
2%
4%
6%
8%
10%
PCI after
discharge*
CABG after
discharge*
CABG PCI
A
Figure 2. Late or Repeat Revascularization
*Discharge landmark time point of discharge, or 7 days if hospitalization was p
Table 5. In-Hospital Events*
MM
(n  2,633)
PCI
(n  4,294)
CABG
(n  1,298)
p
Value
Death 0.9 0.5 1.2 0.027
MI 2.0 9.6 26.6 0.001
Stroke 0.3 0.3 1.3 0.001
Cardiogenic shock 0.6 0.9 3.5 0.001
New onset heart failure 9.9 4 15.5 0.001
GUSTO severe bleed 1.0 0.9 5.9 0.001
TIMI major bleed 1.6 2.1 34.3 0.001
*Events occurring from catheterization through discharge, or 7 days if hospitalization was pro-
longed.uPCI percutaneous coronary intervention; other abbreviations as in Table 4.etermined to not be candidates for revascularization pro-
edures, and these patients have a significantly increased risk
f adverse events, despite widespread use of evidence-based
edications.
easons for nonuse of revascularization procedures. Pos-
ible reasons for patients not undergoing in-hospital revas-
ularization despite significant coronary disease include
eath before planned revascularization, unfavorable coro-
ary anatomy, serious comorbidities, resource availability,
ocioeconomic disparities, and patient refusal. Practice
uidelines recommend consideration of early invasive man-
gement for patients with NSTE ACS who have had prior
evascularization (1), but our data show that patients with
rior CABG were least likely to undergo in-hospital revas-
ularization after early catheterization. Patients with prior
ABG comprise a subgroup in which repeat revasculariza-
ion may be technically challenging due to diffuse native
essel and graft disease (19). Despite the availability of 1
ubgroup analysis of a randomized trial to guide selection of
evascularization strategies in these patients (20), the risk of
eriprocedural adverse events with any revascularization
trategy remains high for patients with prior CABG.
dditionally, many unmeasured variables likely contributed
o decision-making regarding revascularization procedures,
s reflected in the relatively poor c-index (0.64) of the model
e developed to determine predictors of conservative med-
cal management. This matter requires prospective study to
nderstand whether there are opportunities to expand the
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375Data from the CRUSADE (Can Rapid risk stratification
f Unstable angina patients Suppress ADverse outcomes
ith Early implementation of the American College of
ardiology/American Heart Association guidelines) trial
howed that the widespread availability of drug-eluting
tents (DES) from 2003 to 2005 was associated with a sharp
ncrease in PCI use in patients with NSTE ACS and
ignificant CAD, while the rate of CABG procedures
emained relatively stable (8). This was accompanied by a
oncordant decline in the proportion of medically managed
atients, from 49% in 2002 to 36% in 2005, suggesting that
hysicians had become more willing to offer percutaneous
Figure 3. In-Hospital and Post-Discharge Mortality
(A) Death from catheterization through discharge. (B) Death from discharge*
p  0.0001; conservative medical management versus CABG, p  0.08. *Landm
tions as in Figure 1.evascularization options to patients who might have been ronsidered poor candidates for PCI before the advent of
ES. The high rate of off-label DES usage since its
ntroduction, primarily for complex lesion subsets, supports
his conclusion (21). Given recent safety concerns about
ES and uncertainty over the actual benefit of an early
nvasive strategy (22), the proportion of medically managed
atients may remain stable, or actually even increase over
ime.
vidence-based medications. The risk-treatment paradox
efers to progressive diminution in the use of evidence-based
herapies as baseline risk and future probability of death
ncreases (23). However, treatment intensification in high-
gh 1 year. Log-rank p values: conservative medical management versus PCI,
ime point of discharge, or 7 days if hospitalization was prolonged. Abbrevia-throu
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376atients have an increased susceptibility to drug toxicity and
reatment complications (24). The greatest difference in
edication use among the comparison groups was with
lopidogrel, which was targeted for patients who underwent
CI. A subgroup analysis of the CURE (Clopidogrel in
nstable Angina to Prevent Recurrent Ischemic Events)
rial showed a similar benefit of clopidogrel in patients
reated with conservative medical management compared
ith the benefit seen in patients treated with revasculariza-
ion (25). However, in the recent TRITON (Trial to Assess
mprovement in Therapeutic Outcomes by Optimizing
latelet Inhibition With Prasugrel) study, older patients and
hose with lower body weight were also more likely to have
Figure 4. Overall Mortality From Randomization Through 1 Year
Table 6. Post-Discharge Events*
Outcome
MM
(n  2,633)
PCI
(n  4,294)
Adjusted HR  95%
(Mode
Adjusted for Baseline
Characteristics 
In-Hospital Events
All patients
Death/MI at 6 months 11.7% 4.7% 2.01 (1.61–2.51)
MI at 6 months 7.5% 3.3% 1.99 (1.52–2.60)
Death at 1 yr 7.7% 3.6% 1.30 (0.87–1.95)
Censored patients†
Death/MI at 6 months 8.0% 4.7% 1.43 (1.10–1.86)
MI at 6 months 3.7% 3.3% 1.02 (0.72–1.44)
Death at 1 yr 8.0% 3.6% 1.45 (0.96–2.19)
*Only events occurring fromdischarge, or 7 days if hospitalizationwasprolonged,were considered;†
censored in this end point analysis. Outcomes for the in-hospital PCI and CABG groups are the sam
CI confidence interval; HR hazard ratio; other abbreviations as in Table 1.Log-rank MM versus PCI, 0.0001; MM versus CABG, 0.52. Abbreviations as in Figureerious bleeding complications and less likely to derive a net
reatment benefit with more potent thienopyridine treat-
ent (26).
Similar challenges face the widespread implementation of
ntensive lipid-lowering in the medically managed population
ecause of their greater prevalence of comorbid conditions. In
meta-analysis of 4 large clinical trials that included the
ROVE-IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation
nd Infection Therapy–Thrombolysis In Myocardial Infarc-
ion 22) trial (27), investigators confirmed the safety and
fficacy of high-dose statin therapy compared with standard-
ose statin therapy (28). However, patients with serum creat-
nine 2.5 mg/dl were excluded from the aforementioned
MM vs. PCI
CABG
(n  1,298)
Adjusted HR  95% CI for MM vs. CABG
(Model 2)
ted for Baseline
racteristics 
spital Events 
ensity for MM
Adjusted for Baseline
Characteristics 
In-Hospital Events†
Adjusted for Baseline
Characteristics 
In-Hospital Events 
Propensity for MM
9 (1.59–2.49) 4.9% 3.80 (2.65–5.47) 3.47 (2.40–5.02)
2 (1.46–2.52) 1.7% 6.65 (3.74–11.83) 6.27 (3.50–11.23)
2 (0.88–0.97) 6.2% 1.77 (0.98–3.19) 1.83 (1.00–3.37)
8 (1.06–1.80) 4.9% 2.67 (1.81–3.94) 2.36 (1.58–3.53)
4 (0.66–1.35) 1.7% 2.99 (1.61–5.55) 2.66 (1.41–5.00)
8 (0.97–2.26) 6.2% 2.36 (1.24–4.50) 2.54 (1.30–4.97)
ts in the conservativemedicalmanagement groupwhounderwent PCI or CABGwithin 30dayswere
er the “All Patients” analysis in the top rows.CI for
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377linical trials, limiting generalizability of the findings to this
opulation. Impaired renal function is a key concern, and the
ajority of NSTE ACS patients with renal impairment are
anaged medically (29). Hence, questions remain about the
fficacy, safety, and correct dosing of guidelines-recommended
edications in medically managed patients excluded from
andmark randomized controlled trials because of excess co-
orbidity. Dedicated trials with alternative dosing strategies
ay be a step toward resolving concerns regarding drug
etabolism and the increased likelihood of medication side
ffects in this population.
tudy limitations. Several limitations were present with this
nalysis. First, detailed lesion-level angiographic findings
ere not captured, so we were not able to characterize
ngiographic suitability for revascularization. Second, sig-
ificant lesions in the major coronary arteries were recorded
n a dichotomized approach (50% vs. 50%) on the
YNERGY case report form, so we could not assess
ifferent classification schemes for significant coronary dis-
ase such as stenoses 70%. Third, details about physician
ecision-making regarding revascularization were not cap-
ured. However, patients with clinical contraindications to
atheterization and revascularization were excluded from
he SYNERGY trial, so the study population represented an
deal group of patients for early invasive management at the
ime of randomization (30). Fourth, despite our best efforts
o adjust for confounding, the conservative medical man-
gement group represents a particularly high-risk cohort in
hom survival is unlikely to approximate that of the
ower-risk PCI group because of unmeasured confounders
aking it difficult to draw definitive conclusions about the
enefits of early revascularization procedures. Nonetheless,
ur intent was not to show that early revascularization was
ssociated with improved outcomes, but rather to fully
haracterize the short- and long-term risks associated with
 conservative medical management strategy. Last, the
-day landmark analysis, although necessary for the inves-
igation of MI outcomes in this particular study, may
ntroduce biases associated with left censoring of longitudi-
Table 7. Time-Dependent Model Combining In-Hospital and Post-Discharge
Treatment
Group
Unadjusted
1-Year Mortality*, %
Treatment
Comparison
Adjusted for MM as
Time-Dependent
Covariate†
MM 8.9
PCI 4.4 MM vs. PCI 2.30 (1.88–2.82)
CABG 8.2 MM vs. CABG 1.16 (0.91–1.49)
*All events occurring from the time of catheterization through 1 year were considered; †Conser
management versus coronary artery bypass grafting (CABG) modeled as time-dependent covariate
Abbreviations as in Tables 1 and 6.al data.onclusions
lmost one-third of patients with NSTE ACS documented
o have significant coronary disease on angiography did not
ndergo revascularization procedures in the SYNERGY
rial. These patients have a higher risk of long-term adverse
utcomes compared with those who undergo PCI or
ABG despite widespread utilization of guidelines-
ecommended medications. These findings highlight the
eed for novel strategies to mitigate the increased risk of
dverse outcomes in this population and for additional
rospective studies to examine patient and physician
ecision-making regarding revascularization decisions.
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